Induction of Neurotrophic Factors GDNF and BDNF Associated with the Mechanism of Neurorescue Action of Rasagiline and Ladostigil

  title={Induction of Neurotrophic Factors GDNF and BDNF Associated with the Mechanism of Neurorescue Action of Rasagiline and Ladostigil},
  author={Orly Weinreb and Tamar Amit and Orit Bar‐Am and Moussa B. H. Youdim},
  journal={Annals of the New York Academy of Sciences},
Parkinson's disease (PD) and Alzheimer's disease (AD) are the most common neurodegenerative disorders, although there is no drug or therapeutic treatment to demonstrate disease‐modifying effects. Previous work has proposed that neurodegeneration is linked to a lack of trophic support in those neurons and brain areas associated with PD and AD. Indeed, previous studies have found that neurotrophic factors (NTFs) support neuronal survival in various cellular and animal models of PD and AD. Thus… 
Prospects of Neurotrophic Factors for Parkinson's Disease: Comparison of Protein and Gene Therapy.
The emerging and existing possibilities to use NTFs as neurorestorative agents and the ways to improve their efficacy are discussed, and gene therapy and recombinant protein therapy approaches for restoring the dopamine circuitry in PD are compared.
‘‘70th Birthday Professor Riederer’’ Induction of glial cell line-derived and brain-derived neurotrophic factors by rasagiline and (−)deprenyl: a way to a disease-modifying therapy?
The induction of GDNF and BDNF by these MAO inhibitors by rasagiline and (−)deprenyl is reviewed and the induction of prosurvival genes is discussed in relation to a possible disease-modifying therapy withMAO inhibitors in neurodegenerative disorders.
Induction of GDNF and GFRα-1 Following AAV1-Rheb(S16H) Administration in the Hippocampus in vivo
It is suggested that AAV1-Rheb(S16H) transduction of hippocampal neurons, resulting in neurotrophic interactions between neurons and astrocytes, may be useful for neuroprotection in the adult hippocampus.
Phytochemicals That Regulate Neurodegenerative Disease by Targeting Neurotrophins: A Comprehensive Review
The phytochemicals that mediate the signaling pathways involved in neuroprotection specifically neurotrophin-mediated activation of Trk receptors and members of p75NTR superfamily are reviewed.
Challenges and Promises in the Development of Neurotrophic Factor-Based Therapies for Parkinson’s Disease
The current status of the potential relevance of NTFs for treating PD is reviewed, taking into consideration experimental evidence, human observational studies, and data from clinical trials.
Selegiline rescues gait deficits and the loss of dopaminergic neurons in a subacute MPTP mouse model of Parkinson's disease.
Correlation analysis revealed that gait measurement and GDNF/BDNF levels positively correlated with the number of dopaminergic neurons, demonstrating that selegiline has neurorescue effects that are possibly associated with the induction of NTFs and anti-apoptotic genes.
Revelation in the neuroprotective functions of rasagiline and selegiline: the induction of distinct genes by different mechanisms
The authors review their recent results on the molecular mechanisms by which MAO inhibitors prevent the cell death through the induction of antiapoptotic, prosurvival genes in selegiline and rasagiline.
The expanding universe of neurotrophic factors: therapeutic potential in aging and age-associated disorders.
Multiple molecular, cellular, structural and functional changes occur in the brain during aging. Neural cells may respond to these changes adaptively by employing multiple mechanisms in order to
Neurotrophic molecules in the treatment of neurodegenerative disease with focus on the retina: status and perspectives
This article presents selected examples of neurotrophic factors that are currently being tested in animal models or developed for transfer to the clinic, with a major focus on factors with the potential of becoming applicable in various forms of retinal degeneration.
Repairing the parkinsonian brain with neurotrophic factors


Identification of potential compounds promoting BDNF production in nigral dopaminergic neurons: clinical implication in Parkinson's disease
It is demonstrated that salicyclic acid, cGMP analog, okadaic acids, IBMX, dipyridamole and glutamate significantly enhance BDNF production in DA neuronal cells, demonstrating the ability of these compounds to increase the production of BDNF in the DA neurons.
Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo
It is concluded that intracerebral GDNF administration exerts both protective and reparative effects on the nigrostriatal dopamine system, which may have implications for the development of new treatment strategies for Parkinson's disease.
Recent progress in studies of neurotrophic factors and their clinical implications
Physiological experiments indicate that brain-derived neurotrophic factor may serve as regulatory factors for synaptic transmission as well as for learning and memory andGene targeting studies demonstrate that GDNF may be essential for development of the enteric nervous system and kidney organogenesis.
Neurotrophic activities and therapeutic experience with a brain derived peptide preparation.
It is concluded that cerebrolysin is able to induce repair phenomena, resulting in long term stabilization, and tolerability of this drug is extremely high, without any reports about serious side-effects in these clinical studies.
Nerve growth factor: structure, function and therapeutic implications for Alzheimer's disease.
Recent findings indicate an early defect in NGF receptor expression in CBF neurons; therefore treatments aimed at facilitating NGF actions may prove highly beneficial in counteracting the cholinergic dysfunction found in end-stage AD and attenuating the rate of degeneration of these cholinerential neurons.
Neuroprotection by rasagiline: a new therapeutic approach to Parkinson's disease?
Rasagiline has been recently evaluated in early PD patients, with results that are consistent with slowing the progression of the disease, thus providing new perspectives for the treatment of PD.